title: Viability of Human Melanocytes HEMa-LP Exposed to Amikacin and Kanamycin.
abstract: Aminoglycosides, such as amikacin and kanamycin, are powerful broad-spectrum antibiotics used for the treatment of many bacterial infections. The widely used aminoglycosides have the unfortunate side effects of targeting sensory hair cells of the inner ear, so that treatment often results in permanent hair cell loss. The aim of the study was to evaluate the influence of incubation time and drug concentration on viability of melanocytes cultured in the presence of amikacin or kanamycin. The normal human melanocytes HEMa-LP and the different concentrations of amikacin (0.075, 0.75 and 7.5 mmol/l) and kanamycin (0.06, 0.6 and 6.0 mmol/l), were used. The estimations were performed after 24, 48 and 72 h. The observed decrease in melanocytes viability may be an explanation for the mechanisms involved in aminoglycosides toxicity on pigmented tissues during high-dose and/or long-term therapy.
authors.affiliation: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Silesia, Jagiellońska 4, PL 41 200 Sosnowiec, Poland.
authors.forename: D
authors.initials: D
authors.lastname: Wrześniok
authors.forename: M
authors.initials: M
authors.lastname: Otręba
authors.forename: A
authors.initials: A
authors.lastname: Beberok
authors.forename: E
authors.initials: E
authors.lastname: Buszman
keywords: Amikacin; cell viability; kanamycin; melanocytes
references.citation: Hear Res. 1987 Dec 31;31(3):253-65
references.pmid: 3436852
references.citation: Eur J Pharmacol. 2011 Nov 1;669(1-3):32-7
references.pmid: 21871884
references.citation: Eur Arch Otorhinolaryngol. 2002 Jul;259(6):309-15
references.pmid: 12115079
references.citation: Int J Antimicrob Agents. 2009 Mar;33(3):201-5
references.pmid: 18976888
references.citation: Acta Otolaryngol. 1985 Mar-Apr;99(3-4):339-42
references.pmid: 4013723
references.citation: Mutat Res. 2010 Oct;705(2):141-153
references.pmid: 20601102
references.citation: Pharmazie. 2007 Mar;62(3):210-5
references.pmid: 17416198
references.citation: Eur J Pharmacol. 2002 Jun 20;446(1-3):7-13
references.pmid: 12098580
references.citation: Postepy Hig Med Dosw (Online). 2012 Jan 30;66:33-40
references.pmid: 22371403
references.citation: Pigment Cell Res. 1993 Jun;6(3):127-33
references.pmid: 8234197
references.citation: Hear Res. 1989 Aug;41(1):43-51
references.pmid: 2793613
references.citation: Eur J Pharmacol. 2001 May 11;419(2-3):139-45
references.pmid: 11426835
references.citation: Pharmazie. 2008 May;63(5):372-6
references.pmid: 18557422
references.citation: Exp Dermatol. 2009 Sep;18(9):799-819
references.pmid: 19659579
references.citation: Bioorg Med Chem. 2006 Dec 15;14(24):8155-61
references.pmid: 17010622
references.citation: Pharmazie. 2005 Jun;60(6):439-43
references.pmid: 15997833
references.citation: Acta Otolaryngol. 1995 May;115(3):367-74
references.pmid: 7653256